AU2015270924B2 - Peptide-drug conjugates - Google Patents
Peptide-drug conjugates Download PDFInfo
- Publication number
- AU2015270924B2 AU2015270924B2 AU2015270924A AU2015270924A AU2015270924B2 AU 2015270924 B2 AU2015270924 B2 AU 2015270924B2 AU 2015270924 A AU2015270924 A AU 2015270924A AU 2015270924 A AU2015270924 A AU 2015270924A AU 2015270924 B2 AU2015270924 B2 AU 2015270924B2
- Authority
- AU
- Australia
- Prior art keywords
- ala
- asn
- pabc
- cancer
- mitomycin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC[C@](C(Nc1ccc(COC(NC(C[C@](O[C@@](C[C@@](Cc2c(c(C(c3cccc(OC)c33)=O)c4C3=O)O)(C(CO)=O)O)c2c4O)O[C@]2C)[C@]2O)=O)cc1)=O)N*N Chemical compound CC[C@](C(Nc1ccc(COC(NC(C[C@](O[C@@](C[C@@](Cc2c(c(C(c3cccc(OC)c33)=O)c4C3=O)O)(C(CO)=O)O)c2c4O)O[C@]2C)[C@]2O)=O)cc1)=O)N*N 0.000 description 1
- VOTBBYMBGAPTKU-WHFBIAKZSA-N C[C@@H](C(N[C@@H](C)C(C)=O)=O)N Chemical compound C[C@@H](C(N[C@@H](C)C(C)=O)=O)N VOTBBYMBGAPTKU-WHFBIAKZSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462007159P | 2014-06-03 | 2014-06-03 | |
| US62/007,159 | 2014-06-03 | ||
| PCT/US2015/033509 WO2015187540A1 (en) | 2014-06-03 | 2015-06-01 | Peptide-drug conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015270924A1 AU2015270924A1 (en) | 2016-12-15 |
| AU2015270924B2 true AU2015270924B2 (en) | 2019-09-12 |
Family
ID=54700553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015270924A Active AU2015270924B2 (en) | 2014-06-03 | 2015-06-01 | Peptide-drug conjugates |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9579317B2 (enExample) |
| EP (1) | EP3152223B1 (enExample) |
| JP (2) | JP6539729B2 (enExample) |
| CN (1) | CN106456799B (enExample) |
| AU (1) | AU2015270924B2 (enExample) |
| CA (1) | CA2951049C (enExample) |
| ES (1) | ES2857192T3 (enExample) |
| MA (1) | MA40030A (enExample) |
| WO (1) | WO2015187540A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106715457B (zh) | 2014-08-22 | 2021-09-28 | 亚飞（上海）生物医药科技有限公司 | 一种肿瘤微环境特异激活的小分子靶向偶联体及其用途 |
| SG10202008909VA (en) * | 2016-03-24 | 2020-10-29 | Bayer Pharma AG | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| CN107375288B (zh) | 2016-05-16 | 2019-08-23 | 博瑞生物医药（苏州）股份有限公司 | 多臂的聚合靶向抗癌偶联物 |
| US12059472B2 (en) | 2016-12-21 | 2024-08-13 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| CN108314703B (zh) * | 2017-01-17 | 2022-02-01 | 亚飞（上海）生物医药科技有限公司 | 分子定点靶向和激活的激酶抑制剂的制备和用途 |
| KR102279429B1 (ko) * | 2017-04-21 | 2021-07-20 | 브라이트제네 바이오-메디컬 테크놀로지 코., 엘티디. | 멀티 암 표적 항암 콘쥬게이트 |
| CN107670048B (zh) * | 2017-08-30 | 2019-04-26 | 南京明臻医药科技有限公司 | 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用 |
| EP3908307A4 (en) * | 2019-01-07 | 2022-10-12 | Cenna Biosciences Inc. | NOVEL PEPTIDES AND USES THEREOF |
| MX2021011997A (es) * | 2019-04-05 | 2021-11-04 | Prolynx Llc | Enlazadores de conjugacion mejorados. |
| US20220313625A1 (en) * | 2019-05-24 | 2022-10-06 | The Jikei University | Pharmaceutical agent, medicinal solution for cleaning pulmonary alveoli, and nebulizer |
| JP2023548310A (ja) * | 2020-10-30 | 2023-11-16 | アバクタ・ライフ・サイエンシーズ・リミテッド | Ｆａｐ活性化血清半減期延長型治療用コンジュゲート |
| US20230381330A1 (en) * | 2020-10-30 | 2023-11-30 | Avacta Life Sciences Limited | Enzyme-activated serum extended half-life therapeutic conjugates |
| CN115850288B (zh) * | 2022-11-25 | 2025-03-21 | 中科帅天医药(深圳)有限公司 | 一种丝裂霉素c前体药物及其制备方法和应用 |
| IL322909A (en) * | 2023-03-09 | 2025-10-01 | Bicycletx Ltd | Synthesis of bicyclic toxin conjugates and their intermediates |
| CN117683079B (zh) * | 2023-12-12 | 2025-04-04 | 九洲药业(杭州)有限公司 | 一种抗体偶联药物连接子的固相合成方法 |
| TW202613146A (zh) * | 2024-06-11 | 2026-04-01 | 美商克林提克斯醫藥股份有限公司 | 生長抑素亞型-2受體(sst2r)非肽藥物偶聯物及其用途 |
| CN121851112A (zh) * | 2026-03-17 | 2026-04-14 | 内蒙古大学 | 环肽毒素类drug-linker及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3803223A (en) * | 1970-07-20 | 1974-04-09 | Searle & Co | 3-amino-n-substituted succinamic acids and intermediates thereto |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| HUP0300024A2 (en) * | 2000-02-24 | 2003-05-28 | Genentech Inc | Caspase activated prodrugs therapy |
| US8314060B2 (en) | 2000-09-05 | 2012-11-20 | Biosight Ltd. | Peptide conjugated anti-cancer prodrugs |
| EP1635858A4 (en) * | 2003-05-29 | 2009-08-26 | Scripps Research Inst | TARGETED DELIVERY TO LEGUMAIN EXPRESSING CELLS |
| WO2007064759A2 (en) * | 2005-11-29 | 2007-06-07 | The Scripps Research Institute | Inhibiting tumour cell invasion, metastasis and angiogenesis through targetting legumain |
| EP2266964B1 (en) * | 2009-06-22 | 2013-01-09 | KTB Tumorforschungsgesellschaft mbH | Acid-labile trigger units |
| US8394922B2 (en) * | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
| WO2012075472A2 (en) | 2010-12-03 | 2012-06-07 | Regents Of The University Of Colorado, A Body Corporate | Chemical entities and therapeutic uses thereof |
-
2015
- 2015-06-01 JP JP2017516251A patent/JP6539729B2/ja active Active
- 2015-06-01 US US14/726,897 patent/US9579317B2/en active Active
- 2015-06-01 CN CN201580029854.5A patent/CN106456799B/zh active Active
- 2015-06-01 CA CA2951049A patent/CA2951049C/en active Active
- 2015-06-01 AU AU2015270924A patent/AU2015270924B2/en active Active
- 2015-06-01 MA MA040030A patent/MA40030A/fr unknown
- 2015-06-01 EP EP15803150.0A patent/EP3152223B1/en active Active
- 2015-06-01 WO PCT/US2015/033509 patent/WO2015187540A1/en not_active Ceased
- 2015-06-01 ES ES15803150T patent/ES2857192T3/es active Active
-
2017
- 2017-01-27 US US15/417,615 patent/US20170232023A1/en not_active Abandoned
-
2019
- 2019-06-10 JP JP2019107602A patent/JP2019189623A/ja active Pending
Non-Patent Citations (1)
| Title |
|---|
| BAJJURI, K. M. et al. "The Legumain Protease-Activated Auristatin Prodrugs Suppress Tumor Growth and Metastasis without Toxicity", ChemMedChem, 2011, Vol. 6, pages 54-59 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6539729B2 (ja) | 2019-07-03 |
| CN106456799A (zh) | 2017-02-22 |
| ES2857192T3 (es) | 2021-09-28 |
| JP2019189623A (ja) | 2019-10-31 |
| MA40030A (fr) | 2015-12-10 |
| US20150343083A1 (en) | 2015-12-03 |
| US9579317B2 (en) | 2017-02-28 |
| EP3152223A4 (en) | 2017-12-20 |
| WO2015187540A1 (en) | 2015-12-10 |
| EP3152223A1 (en) | 2017-04-12 |
| JP2017521486A (ja) | 2017-08-03 |
| CA2951049A1 (en) | 2015-12-10 |
| CN106456799B (zh) | 2020-05-22 |
| AU2015270924A1 (en) | 2016-12-15 |
| CA2951049C (en) | 2023-01-03 |
| EP3152223B1 (en) | 2020-11-25 |
| US20170232023A1 (en) | 2017-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3152223B1 (en) | Mitomycin conjugate | |
| ES2987765T3 (es) | Suministro dirigido de sustancias farmacéuticas que contienen amina terciaria | |
| WO2015106599A1 (en) | Conjugates and compositions for drug delivery | |
| ES2198421T3 (es) | Derivados de la camptotecina unidos a polimeros. | |
| JP6871858B2 (ja) | 抗体薬物コンジュゲート | |
| ES2919323T3 (es) | Conjugados de compuestos de tubulisina cuaternizados | |
| CA2267493A1 (en) | Glycoconjugates of modified camptothecin derivatives (a- or b-ring linkage) | |
| MX2010012320A (es) | Nuevos conjugados antitumorales de doble orientacion. | |
| CN103044521B (zh) | 天冬氨酸酶靶向激活的阿霉素衍生物、其制备方法和用途 | |
| US11319341B2 (en) | Immune-stimulating soluble doxorubicin-conjugated complex | |
| SK154899A3 (en) | 20(s)- camptothecin glycoconjugates, method for their producing, their use and drugs containing said substances | |
| RS51169B (sr) | Kamptotecini konjugirani na položaju 7 sa cikličnim peptidima kao citostatička sredstva | |
| EP4217007B1 (en) | Peptidic conjugates of sn38 useful in the treatment of cancer | |
| US20020173468A1 (en) | Modified cytostatic agents | |
| WO2023066314A1 (zh) | Nectin-4的双环肽配体及其用途 | |
| AU2010223565A1 (en) | Prodrugs | |
| HK40097010A (en) | Peptidic conjugates of sn38 useful in the treatment of cancer | |
| HK40097010B (en) | Peptidic conjugates of sn38 useful in the treatment of cancer | |
| CN122036864A (zh) | 一种化合物及其制备方法和应用 | |
| KR20010012558A (ko) | 20(ｓ) 캄프토테신 당결합체 | |
| CZ401799A3 (cs) | Glykokonjugáty 20(S)-camptothecinu, způsob jejich výroby, jejich použití a léčiva tyto látky obsahující |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: JIARAY PHARMACEUTICALS, INC. Free format text: FORMER APPLICANT(S): JIARUI BIOPHARMACEUTICALS, LTD. |
|
| FGA | Letters patent sealed or granted (standard patent) |